The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Systemic therapy and overall survival (OS) in patients (pts) with brain metastases from HER2-positive (HER2+) metastatic breast cancer (MBC).
R. Bartsch
No relevant relationships to disclose
A. Berghoff
No relevant relationships to disclose
U. Pluschnig
No relevant relationships to disclose
Z. Bago-Horvath
No relevant relationships to disclose
P. C. Dubsky
No relevant relationships to disclose
A. Rottenfusser
No relevant relationships to disclose
C. Wenzel
No relevant relationships to disclose
M. Rudas
No relevant relationships to disclose
F. Fitzal
No relevant relationships to disclose
K. Dieckmann
No relevant relationships to disclose
M. Gnant
No relevant relationships to disclose
C. Zielinski
No relevant relationships to disclose
G. G. Steger
No relevant relationships to disclose